-
Mashup Score: 42GU ASCO 2024 Highlights with Dr. Tian Zhang – CONTACT-02, BRCAAway, AMBASSADOR, Keynote-564 - 3 month(s) ago
In discussion with Dr. Tian Zhang, covering the Genitourinary ASCO 2024 meeting highlights from the Community Oncology perspective. We covered 4 important practice informing studies from GU ASCO with Dr. Zhang: – CONTACT-02: Phase 3 study of cabozantinib plus atezolizumab vs second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer – BRCAAway: A […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 33
In discussion with Dr. Pamela Kunz, covering the Gastroenterology ASCO 2024 meeting highlights from Community Oncology perspective. We covered 3 important practice informing studies from GI ASCO with Dr. Kunz: – CheckMate 8HW: Nivolumab plus ipilimumab vs chemotherapy as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer – EMERALD-1: A phase 3, […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 20ASH 2023 Leukemia/MDS/Myelofibrosis Highlights – TRANSFORM-1, MANIFEST-2, SAVE, AUGMENT-101 with Dr. Uma Borate - 4 month(s) ago
In discussion with Dr. Uma Borate from the Ohio State University Comprehensive Cancer Center, The James, covering the leukemia, myelofibrosis and myelodysplastic syndrome key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Borate: – TRANSFORM-1: Ph III, Randomized, Double-Blind, […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 50SABCS 2023 HER2+ Breast Cancer Highlights – APHINITY Sub-analysis, KATHERINE update, HER2CLIMB-02 - 4 month(s) ago
In discussion with Dr. Daniel G. Stover, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 3 important practice informing studies in HER2+ disease with Dr. Stover: – APHINITY Sub-analysis: Benefit of Adj Pertuzumab and Trastuzumab According to ER and HER2 Expression – KATHERINE Update: Phase III Study of […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 69SABCS 2023 Breast Cancer Highlights – NATALEE, MONARCH-3, INAVO120, TROPION-Breast01 - 4 month(s) ago
In discussion with Dr. Hope Rugo, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Rugo: – NATALEE Update – Ribociclib + Nonsteroidal AI as Adj Treatment in Patients with HR+/HER2− Early Breast Cancer: Final iDFS analysis – MONARCH 3 – Final […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 22ASH 2023 CLL/Lymphoma Highlights – ALPINE, SEQUOIA, SWOG-S1826, POLARIX Update with Dr. Mazyar Shadman - 5 month(s) ago
In discussion with Dr. Mazyar Shadman from the Fred Hutch Cancer Center, covering the Chronic Lymphocytic Leukemia and Lymphoma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Shadman: – ALPINE: Ph 3, Extended Follow-up Confirms Sustained Superior PFS […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2ASH 2023 Multiple Myeloma Highlights – PERSEUS, IsKia, Bortezomib dosing, KarMMA-3 Update with Dr. Jens Hillengass - 5 month(s) ago
In discussion with Dr. Jens Hillengasss from Roswell Park Comprehensive Cancer Center, covering the Multiple Myeloma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Hillengass: – PERSEUS – Ph 3 Randomized Study of Dara + Bortezomib + Len […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 7ASH 2023 Multiple Myeloma Highlights – PERSEUS, IsKia, Bortezomib dosing, KarMMA-3 Update with Dr. Jens Hillengass - 5 month(s) ago
In discussion with Dr. Jens Hillengasss from Roswell Park Comprehensive Cancer Center, covering the Multiple Myeloma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Hillengass: – PERSEUS – Ph 3 Randomized Study of Dara + Bortezomib + Len […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 19SABCS 2023 Breast Cancer Highlights – NSABP B-51, IDEA Update, ICARO, Keynote 522 Update - 5 month(s) ago
In discussion with Dr. Eleonora Teplinsky, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Teplinsky: – NSABP B-51 – Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node Negative After Neoadjuvant Chemotherapy – IDEA Update […]
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 20How to Treat Myelodysplastic Syndrome (MDS) with Dr. Amer Zeidan - 6 month(s) ago
In discussion with Dr. Amer Zeidan, covering how to treat myelodysplastic syndrome (MDS) in community settings. Dr. Zeidan is the director of early therapeutics research and associate professor of medicine at the Yale School of Medicine – Smilow Cancer Hospital. With Dr. Zeidan we covered MDS management in low-risk and high-risk patient population.
Source: oncbrothers.comCategories: General Medicine News, Partners & KOLsTweet
#GU24 @ASCO Highlights w/ @TiansterZhang - #CONTACT02 - #BRCAAWAY - #AMBASSADOR - #KN564 Full discussion: - https://t.co/wZN3fX0ksh - https://t.co/QXJv5vsWFP - Also on the “Oncology Brothers” podcast #MedTwitter #OncTwitter #gusm @TargetedOnc #MedEd #OncEd https://t.co/8PRp9Gx1Z7